No Carolina / NY / Florida       

      Ph: 561.316.3330

FUNDING

E Tech Group Secures New Investment from Graham Partners, Sets Stage for Continued Growth and Innovation

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.

ROM InWest Invests €1.5 million into AI and Computer Vision Company Kepler Vision Technologies

The investment will allow ROM InWest to further distribute its fall detection product globally.

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”

Kryptos Biotechnologies Secures $10 Mil in Series A Funding | Funds to Be Used for Clinical Studies and FDA Approval of their Molecular...

Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy